HUP0300188A2 - Karbonsavszármazékok, mint IP-antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Karbonsavszármazékok, mint IP-antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0300188A2
HUP0300188A2 HU0300188A HUP0300188A HUP0300188A2 HU P0300188 A2 HUP0300188 A2 HU P0300188A2 HU 0300188 A HU0300188 A HU 0300188A HU P0300188 A HUP0300188 A HU P0300188A HU P0300188 A2 HUP0300188 A2 HU P0300188A2
Authority
HU
Hungary
Prior art keywords
independently
compounds
case
antagonists
preparation
Prior art date
Application number
HU0300188A
Other languages
English (en)
Inventor
Richard Leo Cournoyer
Paul Francis Keitz
Lee Edwin Lowrie
Alexander Victor Muehldorf
Counde O'yang
Dennis Mitsugu Yasuda
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of HUP0300188A2 publication Critical patent/HUP0300188A2/hu
Publication of HUP0300188A3 publication Critical patent/HUP0300188A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

A találmány általában IP receptor antagonistaként felhasználható (I)általános képletű vegyületekre, az egyedi izomerekre, az izomerekracém vagy nemracém keverékeire, továbbá e vegyületek gyógyászatilagalkalmas sóira vagy szolvátjaira vonatkozik. A képletben R1, R2 és R3jelentése egymástól függetlenül mindenesetben arilcsoport vagyheteroaril-csoport; R4 jelentése karboxil- vagy tetrazolil-csoport; ésA jelentése egymástól függetlenül minden esetben egyeskötés, -O(CH2)p-, -S(CH2)p-; -NR1(CH2)p, -(CH2)pO-, -O(CH2)pO-, -(CH2)p-O(CH2)p-, -(CH2)n-CO(CH2)n-, -CONH-, -(CH2)p-, -HC=CH- vagy -C<C-. Bjelentése egymástól függetlenül minden esetben -(CH2)q-, -CH2O-, -CH2OCH2 vagy -CH2NH-; m, p és q jelentése egymástól függetlenül mindenesetben 1, 2 vagy 3; n és r értéke minden esetben egymástólfüggetlenül 0, 1, 2 vagy 3. A találmány továbbá e vegyületekettartalmazó gyógyszerkészítményekre és ezeknek a vegyületeknek azelőállítására és gyógyászati alkalmazására vonatkozik. Ó
HU0300188A 2000-03-16 2001-03-08 Carboxylic acid derivatives as ip antagonists, process for their preparation and pharmaceutical compositions containing them HUP0300188A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19012900P 2000-03-16 2000-03-16
US24712900P 2000-11-10 2000-11-10
PCT/EP2001/002597 WO2001068591A1 (en) 2000-03-16 2001-03-08 Carboxylic acid derivatives as ip antagonists

Publications (2)

Publication Number Publication Date
HUP0300188A2 true HUP0300188A2 (hu) 2003-06-28
HUP0300188A3 HUP0300188A3 (en) 2004-07-28

Family

ID=26885804

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300188A HUP0300188A3 (en) 2000-03-16 2001-03-08 Carboxylic acid derivatives as ip antagonists, process for their preparation and pharmaceutical compositions containing them

Country Status (22)

Country Link
US (3) US6693098B2 (hu)
EP (1) EP1265853A1 (hu)
JP (1) JP3938689B2 (hu)
KR (1) KR100523119B1 (hu)
CN (1) CN1241909C (hu)
AR (1) AR028252A1 (hu)
AU (2) AU5216801A (hu)
BR (1) BR0109235A (hu)
CA (1) CA2401502C (hu)
CZ (1) CZ20023422A3 (hu)
HK (1) HK1054924A1 (hu)
HR (1) HRP20020733A2 (hu)
HU (1) HUP0300188A3 (hu)
IL (1) IL151478A (hu)
MA (1) MA27679A1 (hu)
MX (1) MXPA02008931A (hu)
NO (1) NO328526B1 (hu)
NZ (1) NZ521028A (hu)
PL (1) PL207869B1 (hu)
RU (1) RU2268258C2 (hu)
WO (1) WO2001068591A1 (hu)
YU (1) YU68102A (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2268258C2 (ru) * 2000-03-16 2006-01-20 Ф.Хоффманн-Ля Рош Аг Производные карбоновых кислот в качестве антагонистов ip
MXPA03007865A (es) 2001-03-02 2003-12-04 Hoffmann La Roche Derivados de acido alcoxicarbonilamino benzoico y alcoxicarbonilamino tetrazolil fenilo como antagonistas ip.
CA2438813C (en) 2001-03-02 2008-07-29 F. Hoffmann-La Roche Ag Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as ip antagonists
CN1293042C (zh) * 2002-02-07 2007-01-03 远藤仁 芳香族氨基酸衍生物及其药物组合物
GB2389580A (en) * 2002-06-12 2003-12-17 Bayer Ag 2-Naphthamide PGI2 antagonists
GB2389582A (en) * 2002-06-13 2003-12-17 Bayer Ag Pharmaceutically active carboxamides
KR20050074571A (ko) * 2002-11-11 2005-07-18 바이엘 헬스케어 아게 Ｉｐ 수용체 길항제로서의 페닐 또는 헤테로아릴 아미노알칸 유도체
ATE524741T1 (de) * 2002-12-19 2011-09-15 Scripps Research Inst Zusammensetzungen und verwendungen zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
WO2004069805A1 (en) * 2003-02-10 2004-08-19 Bayer Healthcare Ag Bis(hetero)aryl carboxamide derivatives for use as pgi2 antagonists
US20060171945A1 (en) * 2003-02-14 2006-08-03 Critchley Hilary Octavia D Ip receptor antagonists for the treatment of pathological uterine conditions
DE10332560B4 (de) * 2003-07-11 2010-07-08 Chiracon Gmbh Verfahren zur Herstellung von ß- Heteroaryl-2-alanin-Verbindungen über 2-Amino-2-(heteroarylmethyl)-carbonsäure-Verbindungen
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
JP2007538103A (ja) * 2004-05-20 2007-12-27 ザ スクリップス リサーチ インスティテュート トランスサイレチン安定化
WO2006029735A1 (en) * 2004-09-15 2006-03-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with prostaglandin 12 receptor (ptgir)
CA2645099A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for modulating bladder function
WO2008034016A2 (en) * 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
TWI449040B (zh) * 2006-10-06 2014-08-11 Crocus Technology Sa 用於提供內容可定址的磁阻式隨機存取記憶體單元之系統及方法
KR20230085944A (ko) * 2008-03-18 2023-06-14 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
ATE538474T1 (de) * 2008-04-07 2012-01-15 Crocus Technology Sa System und verfahren zum schreiben von daten auf magnetoresistive direktzugriffsspeicherzellen
EP2124228B1 (en) * 2008-05-20 2014-03-05 Crocus Technology Magnetic random access memory with an elliptical junction
US8031519B2 (en) * 2008-06-18 2011-10-04 Crocus Technology S.A. Shared line magnetic random access memory cells
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
LT2593452T (lt) * 2010-07-14 2017-04-10 Novartis Ag Heterocikliniai junginiai, kaip ip receptoriaus agonistai
EP2609075B1 (en) * 2010-08-23 2016-03-16 Novartis AG Process for the preparation of intermediates for the manufacture of nep inhibitors
WO2013038351A1 (en) 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
JP6073923B2 (ja) * 2012-01-13 2017-02-01 ノバルティス アーゲー 肺動脈高血圧症（ｐａｈ）および関連障害の治療のためのｉｐ受容体アゴニストとしての縮合ピロール
WO2014143592A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid ip receptors
WO2014143591A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
WO2017019175A1 (en) * 2015-07-24 2017-02-02 Newlink Genetics Corporation Salts and prodrugs of 1-methyl-d-tryptophan
KR20220119169A (ko) 2017-03-01 2022-08-26 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
PE20210367A1 (es) 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
CN111408314B (zh) * 2020-04-17 2021-08-10 甘肃智仑新材料科技有限公司 一种含炔基阳离子表面活性剂及其制备方法
KR20230158076A (ko) * 2021-03-18 2023-11-17 제니비젼 인크. 눈 질환을 치료하기 위한 방법 및 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB895344A (en) 1957-08-30 1962-05-02 Ciba Ltd Method of temporary protection of hydroxy, mercapto and amino groups
US3875207A (en) * 1967-01-25 1975-04-01 Ciba Geigy Corp Process for the temporary protection of amino groups in peptide syntheses
DE1793827A1 (de) 1967-01-25 1976-05-13 Ciba Geigy Ag Neue aminoschutzgruppen, ihre verwendung bei peptidsynthesen und verfahren zur herstellung der entsprechend geschuetzten aminosaeuren und peptide
DE1934783A1 (de) 1969-07-09 1971-01-28 Bayer Ag Biphenylisopropyloxycarbonylfluorid und seine Verwendung zur Acylierung von Aminosaeuren
DE2641060A1 (de) 1976-09-11 1978-03-16 Hoechst Ag Beta-lactamverbindungen und verfahren zu ihrer herstellung
US4145337A (en) * 1977-10-11 1979-03-20 Hoffmann-La Roche Inc. Aminoethylglycine containing polypeptides
JPH0672985B2 (ja) 1986-05-29 1994-09-14 株式会社ハツコウ メガネ枠フイツテイング調整システム
NZ221729A (en) 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
US5250517A (en) 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
JP3507494B2 (ja) 1992-08-13 2004-03-15 ワーナー−ランバート・コンパニー タキキニン拮抗薬
JPH0672985A (ja) 1992-08-28 1994-03-15 Ono Pharmaceut Co Ltd （チオ）ウレア誘導体
JP3118738B2 (ja) 1992-12-22 2000-12-18 小野薬品工業株式会社 （チオ）ウレア誘導体
NZ287284A (en) 1994-06-06 1998-10-28 Warner Lambert Co N-[2-(phenyl(substituted)ethylamino)-1-(indolylmethyl)-1-methyl -2-oxoethyl] carbamic acid ester derivatives, medicaments and intermediates
DE19544687A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK0888292T3 (da) * 1996-03-20 2002-02-18 Genentech Inc Tricykliske forbindelser med virkning over for integriner, især alphavbeta3 integriner, fremgangsmåde til deres fremstilling, mellemprodukter deraf, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf
NZ331480A (en) * 1997-09-04 2000-02-28 F 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions
RU2268258C2 (ru) * 2000-03-16 2006-01-20 Ф.Хоффманн-Ля Рош Аг Производные карбоновых кислот в качестве антагонистов ip

Also Published As

Publication number Publication date
US20030220367A1 (en) 2003-11-27
BR0109235A (pt) 2002-12-17
WO2001068591A1 (en) 2001-09-20
HK1054924A1 (en) 2003-12-19
AR028252A1 (es) 2003-04-30
JP3938689B2 (ja) 2007-06-27
PL358216A1 (en) 2004-08-09
US20010056100A1 (en) 2001-12-27
IL151478A (en) 2009-07-20
CA2401502C (en) 2010-09-21
HUP0300188A3 (en) 2004-07-28
US7056903B2 (en) 2006-06-06
RU2268258C2 (ru) 2006-01-20
US20060035870A1 (en) 2006-02-16
CZ20023422A3 (cs) 2003-01-15
US7312230B2 (en) 2007-12-25
MA27679A1 (fr) 2006-01-02
US6693098B2 (en) 2004-02-17
NO20024387L (no) 2002-10-21
KR100523119B1 (ko) 2005-10-20
AU5216801A (en) 2001-09-24
NO328526B1 (no) 2010-03-08
PL207869B1 (pl) 2011-02-28
NZ521028A (en) 2004-07-30
KR20020091135A (ko) 2002-12-05
HRP20020733A2 (en) 2005-02-28
CN1418187A (zh) 2003-05-14
NO20024387D0 (no) 2002-09-13
AU2001252168B2 (en) 2007-07-12
CA2401502A1 (en) 2001-09-20
EP1265853A1 (en) 2002-12-18
CN1241909C (zh) 2006-02-15
YU68102A (sh) 2006-01-16
MXPA02008931A (es) 2003-02-10
RU2002127781A (ru) 2004-03-20
JP2003527368A (ja) 2003-09-16

Similar Documents

Publication Publication Date Title
HUP0300188A2 (hu) Karbonsavszármazékok, mint IP-antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
FI941987A (fi) Uudet aminohappojohdannaiset, menetelmät niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset
PL398536A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
HUP0301195A2 (hu) Alfa-4 integrin antagonista hatású aza-hidas biciklusos aminosav-származékok és ilyen vegyületeket tartalmazó gyógyszerkészítmények
DE59010017D1 (de) Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EA199800794A1 (ru) Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения
HUP0101511A2 (hu) 1-[(1-Szubsztituált-4-piperidinil)-metil]-4-piperidin-származékok, eljárás a vegyületek előállítására, a vegyületeket tartalmazó gyógyászati készítmények és intermedierjeik
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
IL155333A0 (en) Sulfanilide derivatives for use in medicine, certain such new derivatives and their preparation
NO974734D0 (no) Arylglycinamidderivater, fremgangsmåte for fremstilling av disse forbindelsene og farmasöytiske blandinger inneholdende slike forbindelser
YU22996A (sh) Novi derivati arilglicinamida postupci za njihovo pripremanje i farmaceutski preparati koji sadrže ova jedinjenja
NO172580C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte n-(1-alkyl-3-hydroksy-4-piperidinyl)benzamider
DE69431069D1 (de) Cyclische amidderivate als neurokinin a antagonisten
NO973652L (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreseptor-antagonist
TNSN97014A1 (fr) Piperidones, procedes pour leur preparation et compositions pharmaceutiques les contenant.
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
FI963440A (fi) Uudet aminohappojohdannaiset, näiden valmistusmenetelmä ja näitä yhdisteitä sisältävät farmaseuttiset seokset
HUP9901208A2 (hu) (R)-5-Bróm-n-(1-etil-4-metil-hexahidro-1H-1,4-diazepin-6-il)-2-metoxi-6-(metil-amino)-3-piridin-karboxamid, eljárás előállítására és ezt a vegyületet tartalmazó gyógyászati készítmény
GR1001068B (el) Νέον παράγωγον 5Η-βενζοδιαζεπίνης, φαρμακευτικαί συν?έσεις περιέχουσαι τούτο, και μέ?οδος δια την παρασκευήν αυτών.
TR200103473T2 (tr) Kristalli azabisiklo (2.2.2) oktan-3-amin sitratin polimorfları ve farmasötik kompozisyonları.
HUP0203650A2 (hu) Heterociklusos származékok, eljárás az előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0000307A2 (hu) Y Neuropeptid antagonisták és ezeket tartalmazó gyógyászati készítmények
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0004177A2 (hu) 4,5-Diaril-oxazol származékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
CA2426221A1 (en) New neurokinin antagonists, processes for preparing them and pharmaceutical compositions containing these compounds

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees